Schizandrin A | CAS#61281-38-7 | AMPK/Nrf2 pathway regulator

MedKoo Cat#: 555462 | Name: Schizandrin A

Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Schizandrin A, also known as Deoxyschizandrin, is a bio-active isolate of Schisandra chinensis. Schizandrin A protects against cerebral ischemia-reperfusion injury by suppressing inflammation and oxidative stress and regulating the AMPK/Nrf2 pathway regulation. Schisandrin A prevents oxidative stress-induced DNA damage and apoptosis by attenuating ROS generation in C2C12 cells.

Chemical Structure

Schizandrin A

CAS#61281-38-7

Theoretical Analysis

MedKoo Cat#: 555462

Name: Schizandrin A

CAS#: 61281-38-7

Chemical Formula: C24H32O6

Exact Mass: 416.2199

Molecular Weight: 416.51

Elemental Analysis: C, 69.21; H, 7.74; O, 23.05

Price and Availability

Size	Price	Availability	Quantity
25mg	USD 450.00
100mg	USD 1,000.00

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

No Data

Synonym

Deoxyschisandrin; Deoxyschizandrin; Schizandrin A; Schisandrin A

IUPAC/Chemical Name

(6R,7S)-1,2,3,10,11,12-Hexamethoxy-6,7-dimethyl-5,6,7,8-tetrahydrodibenzo[a,c][8]annulene

InChi Key

JEJFTTRHGBKKEI-OKILXGFUSA-N

InChi Code

InChI=1S/C24H32O6/c1-13-9-15-11-17(25-3)21(27-5)23(29-7)19(15)20-16(10-14(13)2)12-18(26-4)22(28-6)24(20)30-8/h11-14H,9-10H2,1-8H3/t13-,14+

SMILES Code

C[C@H]1CC2=CC(OC)=C(OC)C(OC)=C2C3=C(OC)C(OC)=C(OC)C=C3C[C@H]1C

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>3 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Product Data

Product Data

Instruction

View handling instruction

Biological target:

Schizandrin A inhibits CYP3A activity with an IC50 of 6.60 μM and Ki of 5.83 μM.

In vitro activity:

The findings of this study suggest that schizandrin A has inhibitory effects on non‑small cell lung cancer (NSCLC), involving cell cycle arrest, apoptosis, and partial activation of autophagy. Schizandrin A resulted in decreased NSCLC cell viability and proliferation. At low concentrations, Schizandrin A induced G1/S-phase cell cycle arrest, while higher concentrations led to apoptosis and G2/M-phase cell cycle arrest. The expression of cell cycle-related proteins varied with schizandrin A concentration. Reference: Int J Mol Med. 2021 Dec;48(6):214. https://pubmed.ncbi.nlm.nih.gov/34643254/

In vivo activity:

Schizandrin A could be a potential therapeutic treatment for nonalcoholic fatty liver disease (NAFLD). In male C57BL/6J mice, schizandrin A alleviated high-fat and high-cholesterol (HFHC) diet-induced NAFLD by regulating hepatic lipid metabolism and oxidative stress. Reference: Nutr Res. 2019 Apr;64:64-71. https://pubmed.ncbi.nlm.nih.gov/30802724/

	Solvent	mg/mL	mM
Solubility
	DMSO	50.0	120.05

Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 416.51 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

Formulation protocol:

1. Zhu L, Wang Y, Lv W, Wu X, Sheng H, He C, Hu J. Schizandrin A can inhibit non‑small cell lung cancer cell proliferation by inducing cell cycle arrest, apoptosis and autophagy. Int J Mol Med. 2021 Dec;48(6):214. doi: 10.3892/ijmm.2021.5047. Epub 2021 Oct 13. PMID: 34643254; PMCID: PMC8522958. 2. Chen BC, Tu SL, Zheng BA, Dong QJ, Wan ZA, Dai QQ. Schizandrin A exhibits potent anticancer activity in colorectal cancer cells by inhibiting heat shock factor 1. Biosci Rep. 2020 Mar 27;40(3):BSR20200203. doi: 10.1042/BSR20200203. PMID: 32110802; PMCID: PMC7069920. 3. Cui L, Zhu W, Yang Z, Song X, Xu C, Cui Z, Xiang L. Evidence of anti-inflammatory activity of Schizandrin A in animal models of acute inflammation. Naunyn Schmiedebergs Arch Pharmacol. 2020 Nov;393(11):2221-2229. doi: 10.1007/s00210-020-01837-x. Epub 2020 Feb 19. PMID: 32076762. 4. Jeong MJ, Kim SR, Jung UJ. Schizandrin A supplementation improves nonalcoholic fatty liver disease in mice fed a high-fat and high-cholesterol diet. Nutr Res. 2019 Apr;64:64-71. doi: 10.1016/j.nutres.2019.01.001. Epub 2019 Jan 11. PMID: 30802724.

In vitro protocol:

In vivo protocol:

1. Cui L, Zhu W, Yang Z, Song X, Xu C, Cui Z, Xiang L. Evidence of anti-inflammatory activity of Schizandrin A in animal models of acute inflammation. Naunyn Schmiedebergs Arch Pharmacol. 2020 Nov;393(11):2221-2229. doi: 10.1007/s00210-020-01837-x. Epub 2020 Feb 19. PMID: 32076762. 2. Jeong MJ, Kim SR, Jung UJ. Schizandrin A supplementation improves nonalcoholic fatty liver disease in mice fed a high-fat and high-cholesterol diet. Nutr Res. 2019 Apr;64:64-71. doi: 10.1016/j.nutres.2019.01.001. Epub 2019 Jan 11. PMID: 30802724.

1: Jia S, Guan H, Zhang S, Li Q. Schisandrin A Alleviates Inflammation and Oxidative Stress in Aβ25-35-Induced Alzheimer's Disease in Vitro Model. Actas Esp Psiquiatr. 2024 Oct;52(5):724-732. doi: 10.62641/aep.v52i5.1680. PMID: 39403912; PMCID: PMC11474961. 2: Sheng Y, Dong J, Wang R, Wang Y, Huang X, Chen C. The influence of storage conditions on the quality of Schisandra chinensis fruits: A integrated investigation of constituent and antioxidant activity. Heliyon. 2024 May 29;10(11):e32194. doi: 10.1016/j.heliyon.2024.e32194. PMID: 38882346; PMCID: PMC11176920. 3: Hu L, Zhang Z, Zhu F, Li X, Zou M, Yang R. Schizandrin A enhances the sensitivity of gastric cancer cells to 5-FU by promoting ferroptosis. Cytotechnology. 2024 Jun;76(3):329-340. doi: 10.1007/s10616-024-00623-4. Epub 2024 Mar 25. PMID: 38736724; PMCID: PMC11082097. 4: He D, Pei X, Liu B, Li J, Dong J, Efferth T, Ma P. Lignan contents of Schisandra chinensis (Turcz.) Baill. from different origins-A new model for evaluating the content of prominent components of Chinese herbs. Phytomedicine. 2024 Jun;128:155361. doi: 10.1016/j.phymed.2024.155361. Epub 2024 Jan 15. PMID: 38552434. 5: Ding Y, Guo N, Jiang Y, Liu S, Zhou T, Bai H, Lv Y, Han S, He L. Establishment of cluster of differentiation 20 immobilized cell membrane chromatography for the screening of active antitumor components in traditional Chinese medicine. J Chromatogr A. 2024 Apr 26;1721:464845. doi: 10.1016/j.chroma.2024.464845. Epub 2024 Mar 24. PMID: 38552371. 6: Wang X, Wang F, Dong P, Zhou L. The therapeutic effect of ultrasound targeted destruction of schisandrin A contrast microbubbles on liver cancer and its mechanism. Radiol Oncol. 2024 Mar 7;58(2):221-233. doi: 10.2478/raon-2024-0019. PMID: 38452391; PMCID: PMC11165982. 7: Poynter ME, Mank MM, Ather JL. Obesity-associated inflammatory macrophage polarization is inhibited by capsaicin and phytolignans. Am J Physiol Regul Integr Comp Physiol. 2024 May 1;326(5):R370-R382. doi: 10.1152/ajpregu.00161.2023. Epub 2024 Mar 4. PMID: 38436058; PMCID: PMC11398870. 8: Liu HL, Huang Z, Li QZ, Cao YZ, Wang HY, Alolgab RN, Deng XY, Zhang ZH. Schisandrin A alleviates renal fibrosis by inhibiting PKCβ and oxidative stress. Phytomedicine. 2024 Apr;126:155372. doi: 10.1016/j.phymed.2024.155372. Epub 2024 Jan 17. PMID: 38382281. 9: Zhu L, Wang Y, Huang X, Liu X, Ye B, He Y, Yu H, Lv W, Wang L, Hu J. Schizandrin A induces non-small cell lung cancer apoptosis by suppressing the epidermal growth factor receptor activation. Cancer Med. 2024 Jan;13(2):e6942. doi: 10.1002/cam4.6942. PMID: 38376003; PMCID: PMC10877655. 10: Huang S, Song W, Jiang S, Li Y, Wang M, Yang N, Zhu H. Pharmacokinetic interactions between tacrolimus and Wuzhi capsule in liver transplant recipients: Genetic polymorphisms affect the drug interaction. Chem Biol Interact. 2024 Mar 1;391:110906. doi: 10.1016/j.cbi.2024.110906. Epub 2024 Feb 8. PMID: 38340974. 11: Jin J, Chen M, Wang H, Li S, Ma L, Wang B. Schizandrin A attenuates early brain injury following subarachnoid hemorrhage through suppressing neuroinflammation. Mol Biol Rep. 2024 Jan 29;51(1):236. doi: 10.1007/s11033-023-08956-7. PMID: 38285214. 12: Xiao Y, Zhou H, Cui Y, Zhu X, Li S, Yu C, Jiang N, Liu L, Liu F. Schisandrin A enhances pathogens resistance by targeting a conserved p38 MAPK pathway. Int Immunopharmacol. 2024 Feb 15;128:111472. doi: 10.1016/j.intimp.2023.111472. Epub 2024 Jan 4. PMID: 38176342. 13: Lin LJ, Zhang MX, Li H, Lan XM, Wei XL, Guo C, Yang B. [Identification of Q-markers for Schisandrae Sphenantherae Fructus in treating drug-induced liver injury based on network pharmacology, fingerprint and quantitative analysis]. Zhongguo Zhong Yao Za Zhi. 2023 Oct;48(20):5460-5473. Chinese. doi: 10.19540/j.cnki.cjcmm.20230627.201. PMID: 38114139. 14: Kim HJ, Park SK, Park SH, Lee YG, Park JH, Hwang JT, Chung MY. Schisandrin A in Schisandra chinensis Upregulates the LDL Receptor by Inhibiting PCSK9 Protein Stabilization in Steatotic Model. J Microbiol Biotechnol. 2024 Feb 28;34(2):425-435. doi: 10.4014/jmb.2306.06049. Epub 2023 Oct 31. PMID: 37997262; PMCID: PMC10940739. 15: Zhao C, Rollo B, Shahid Javaid M, Huang Z, He W, Xu H, Kwan P, Zhang C. An integrated in vitro human iPSCs-derived neuron and in vivo animal approach for preclinical screening of anti-seizure compounds. J Adv Res. 2024 Oct;64:249-262. doi: 10.1016/j.jare.2023.11.022. Epub 2023 Nov 22. PMID: 37995945; PMCID: PMC11464642. 16: Guo X, Lei M, Ma G, Ouyang C, Yang X, Liu C, Chen Q, Liu X. Schisandrin A Alleviates Spatial Learning and Memory Impairment in Diabetic Rats by Inhibiting Inflammatory Response and Through Modulation of the PI3K/AKT Pathway. Mol Neurobiol. 2024 May;61(5):2514-2529. doi: 10.1007/s12035-023-03725-w. Epub 2023 Nov 1. PMID: 37910285. 17: Bin Z, Ning YU, Lei W, Yue T, Mingfen WU, Zhigang Z. Synergistic effect of schizandrin A and DNase I knockdown on high glucose induced beta cell apoptosis by decreasing intracellular calcium concentration. J Tradit Chin Med. 2023 Aug;43(4):661-666. doi: 10.19852/j.cnki.jtcm.2023.04.003. PMID: 37454250; PMCID: PMC10320450. 18: Zeng J, Liao S, Liang Z, Li C, Luo Y, Wang K, Zhang D, Lan L, Hu S, Li W, Lin R, Jie Z, Hu Y, Dai S, Zhang Z. Schisandrin A regulates the Nrf2 signaling pathway and inhibits NLRP3 inflammasome activation to interfere with pyroptosis in a mouse model of COPD. Eur J Med Res. 2023 Jul 3;28(1):217. doi: 10.1186/s40001-023-01190-8. PMID: 37400851; PMCID: PMC10316617. 19: Qiu Q, Zhang W, Liu K, Huang F, Su J, Deng L, He J, Lin Q, Luo L. Schisandrin A ameliorates airway inflammation in model of asthma by attenuating Th2 response. Eur J Pharmacol. 2023 Aug 15;953:175850. doi: 10.1016/j.ejphar.2023.175850. Epub 2023 Jun 15. PMID: 37329976. 20: You LJ, Li PW, Zhang WW, Feng MF, Zhao WP, Hou HM, Piao XM, Wang LB, Zhang Y. Schisandrin A ameliorates increased pulmonary capillary endothelial permeability accompanied with sepsis through inhibition of RhoA/ROCK1/MLC pathways. Int Immunopharmacol. 2023 May;118:110124. doi: 10.1016/j.intimp.2023.110124. Epub 2023 Apr 5. PMID: 37028276.